Cypherpunk Technologies (NASDAQ:CYPH – Get Free Report) Director Thomas John Dietz sold 20,000 shares of the stock in a transaction on Wednesday, August 26th. The shares were sold at an average price of $1.72, for a total value of $34,400.00. Following the completion of the sale, the director directly owned 132,500 shares of the company’s stock, valued at $227,900. The trade was a 13.11% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the SEC, which is available through this link.
Cypherpunk Technologies Price Performance
CYPH opened at $1.71 on Friday. The company has a market capitalization of $184.28 million, a price-to-earnings ratio of 3.05 and a beta of 0.09. The firm’s fifty day moving average price is $0.81 and its two-hundred day moving average price is $0.82. Cypherpunk Technologies has a 1 year low of $0.27 and a 1 year high of $3.70.
Cypherpunk Technologies (NASDAQ:CYPH – Get Free Report) last announced its earnings results on Wednesday, August 12th. The company reported $0.18 EPS for the quarter.
Analyst Upgrades and Downgrades
Institutional Investors Weigh In On Cypherpunk Technologies
Large investors have recently modified their holdings of the stock. Acadian Asset Management LLC lifted its stake in Cypherpunk Technologies by 470.4% in the first quarter. Acadian Asset Management LLC now owns 1,280,531 shares of the company’s stock valued at $389,000 after purchasing an additional 1,056,047 shares during the last quarter. Sequoia Financial Advisors LLC purchased a new stake in shares of Cypherpunk Technologies during the fourth quarter worth $56,000. HighTower Advisors LLC purchased a new stake in Cypherpunk Technologies during the 4th quarter worth about $59,000. Simplify Asset Management Inc. purchased a new stake in shares of Cypherpunk Technologies in the fourth quarter worth about $2,172,000. Finally, Texas Capital Bank Wealth Management Services Inc bought a new position in Cypherpunk Technologies in the 4th quarter valued at $121,000. Hedge funds and other institutional investors own 30.46% of the company’s stock.
Cypherpunk Technologies Company Profile
Cypherpunk Technologies Inc, previously known as Leap Therapeutics, Inc, is a company developing novel therapies for patients with cancer and implementing a digital asset treasury strategy focused on Zcash. The company’s research platform centers on modulating the tumor microenvironment to enhance anti-tumor immune responses. Cypherpunk’s proprietary pipeline includes DKN-01, a monoclonal antibody designed to neutralize Dickkopf-1 (DKK1), a protein implicated in tumor growth and immune evasion.
DKN-01 is being evaluated both as a monotherapy and in combination with checkpoint inhibitors such as pembrolizumab across multiple solid tumor indications, including gastroesophageal, pancreatic and other advanced malignancies.
Read More
- Five stocks we like better than Cypherpunk Technologies
- From SaaS-pocalypse to Perfect Storm: Workday’s AI Growth Story Strengthens
- These 3 GARP Stocks Show Why Growth and Value Do Not Have to Clash
- Venture Into High-Volatility Corners of the Market With These 3 ETFs
- 3 Retail Stocks to Watch After a Big Consumer Earnings Week
Receive News & Ratings for Cypherpunk Technologies Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cypherpunk Technologies and related companies with MarketBeat.com's FREE daily email newsletter.
